7th Annual Live Medical Crossfire®: Hematologic Malignancies
MRD Assessment as a Cornerstone to Clinical Decision-Making in Hematologic Malignancies: Techniques, Utilization, and Best Practices to Optimize Patient Outcomes
Medical Crossfire®: Antibody-Drug Conjugates Coming to Your Oncology Practice Tomorrow
Addressing Clinical Gaps in Thyroid Cancer Management: Taking Action with Precision Methods to Personalize Treatment Decision-Making
State-of-the-Art CMV Care: Experts’ Perspectives on Primary/Secondary Prevention and Management of Refractory/Resistant Infections
Medical Crossfire®: Clinical Decision-Making Under New Paradigms for HR+/HER2- Breast Cancer
Evolving Evidence in Pediatric Brain Cancer: Spotlight on MAPK Inhibitors
Follicular Lymphoma Workshop: Forging Patient-Centric Plans with Targeted Therapies Across Lines of Care
Dostarlimab/Chemo Preserves HRQOL in Advanced/Recurrent Endometrial CancerJune 4th 2023
Health-related quality of life data support dostarlimab plus chemotherapy as a standard of care in primary advanced or recurrent endometrial cancer, according to an expert from Copenhagen University Hospital in Denmark.
Preoperative FOLFOX Appears Noninferior Vs CRT in Rectal Cancer
“We think that we can successfully de-escalate treatment of rectal cancer and achieve the same high cure rates [and] keep patients disease free, with less long-term toxicity and effects,” lead author Deb Schrag, MD, FASCO, MPH, said.
Single-Agent Elranatamab Garners Robust, Durable Responses in Advanced Myeloma
For the pooled analysis, investigators evaluated the efficacy and safety of bispecific antibody elranatamab in patients with relapsed/refractory multiple myeloma enrolled in 1 of the 4 MagnetisMM trials who received at least 1 proteasome inhibitor, 1 immunomodulatory drug, 1 anti-CD38 monoclonal antibody, and 1 BCMA-directed ADC and/or CAR T-cell therapy.
Nivolumab Boosts Survival Vs Brentuximab Vedotin in Advanced Hodgkin Lymphoma
SWOG S1826 is an open-label trial that enrolled patients with newly diagnosed stage III or IV classical Hodgkin lymphoma who were randomly assigned to receive either nivolumab/AVD or brentuximab vedotin/AVD.
Dostarlimab Yields ‘Transformative Benefit’ In Endometrial Cancer SubgroupJune 3rd 2023
The dostarlimab produced a survival benefit vs placebo in combination with standard of care therapy regardless of whether patients had mismatch repair deficient/microsatellite instability-high disease.
Radium-223 Can Be ‘Integrated into Treatment Sequencing’ in Metastatic CRPCJune 3rd 2023
According to an expert from Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, radium-223 shows positive efficacy and safety findings for patients with metastatic castration-resistant prostate cancer.
Talazoparib/Enzalutamide Combo Appears Tolerable in Prostate CancerJune 3rd 2023
A recent phase 3 trial of the combination included a total of 398 patients with metastatic castration-resistant prostate cancer, unselected for homologous recombination repair gene alterations, in the safety cohort.
Perioperative Pembrolizumab Improves Responses in Early-Stage NSCLCJune 3rd 2023
For patients with early-stage non–small cell lung cancer, the addition of pembrolizumab to neoadjuvant platinum-based chemotherapy followed by resection and adjuvant pembrolizumab as a monotherapy results in a significant improvement in event-free survival and pathological response.